

**Table S1** Published cases of paediatric SCSG

Author, year	Age (years), sex	Site, size (cm)	Tumour invasion	Nodal spread or distant metastasis	Local surgery	Neck dissection	Adjuvant therapy	Outcome
Griffith <i>et al.</i> , 2011 (29)	15, male	Upper lip minor salivary gland, 1	T1	Nil	–	–	–	–
Rastatter <i>et al.</i> , 2012 (23)	14, female	Right parotid gland, 3	T2, nil LVI, nil PNI	N1 (1 periparotid lymph node positive for metastatic carcinoma), M0	Right total parotidectomy	Right selective neck dissection	Nil	No evidence of disease 12 months postoperatively
Connor <i>et al.</i> , 2012 (30)	14, –	7 cases, data not stratified by case	7 cases, data not stratified by case	7 cases, data not stratified by case	7 cases, data not stratified by case	7 cases, data not stratified by case	7 cases, data not stratified by case	7 cases, data not stratified by case
Hwang <i>et al.</i> , 2014 (9)	13, male	Left parotid gland, 3	Nil LVI, nil PNI	Nil	Left parotid tumour excision	Nil	Nil	Postoperative course uneventful after 8-month follow-up
Woo <i>et al.</i> , 2014 (31)	14, male	Left parotid gland, 1.9	Facial nerve involvement, nil PNI	Nil	Left superficial parotidectomy with facial nerve dissection. Proximal end upper division facial nerve sacrifice and greater auricular nerve cable graft	Nil	Nil	–
Keisling <i>et al.</i> , 2014 (32)	5, female	Right buccal mucosa minor salivary gland, –	–	–	Complete tumour excision	–	–	Further excision recommended, lost to follow-up
Inaba <i>et al.</i> , 2015 (10)	15, female	Left parotid gland, –	T1, nil LVI, nil PNI	Nil	Left total parotidectomy	Nil	Nil	No evidence of disease 40 months after surgery
Quattlebaum <i>et al.</i> , 2015 (33)	15, female	Left parotid gland, 3	T1	N0 (1 adjacent parotid lymph node on fine needle aspirate, no evidence of malignancy)	Left superficial parotidectomy with facial nerve dissection	Nil	Nil	–
Joshi <i>et al.</i> , 2015 (25)	15, male	Right parotid gland, 20	Nil LVI, nil PNI	N0 (0/17 nodes dissected, no evidence of malignancy)	Right total parotidectomy with facial nerve and spinal accessory nerve dissection	Neck dissection	Nil	–
Shah <i>et al.</i> , 2015 (34)	16, female	Right parotid gland, –	Nil LVI	Nil	–	–	–	–
Urano <i>et al.</i> , 2015 (35)	14, female	Parotid gland, 2.8	T2	Nil	Parotid tumour excision	Nil	Nil	Alive without disease
Ito <i>et al.</i> , 2015 (36)	10, female	Submandibular gland, 3.8	Nil LVI, nil PNI	Nil	Submandibular tumour excision	Nil	Nil	–
Skálová <i>et al.</i> , 2016 (2 cases) (20)	A: 15, male B: 17, male	A: submandibular gland, 1.8 B: parotid gland, 4	A: invasive at capsule, close margins <0.5 mm, with PNI B: T2, invasive at capsule, clear margins, nil LVI, nil PNI	A: N2bM0 B: nil	A: submandibular tumour excision B: parotid tumour excision	A: yes B: nil	A: radiotherapy B: nil	A: no evidence of disease at 4 years B: no evidence of disease at 144 months
Khurram <i>et al.</i> , 2016 (37)	12, –	11 cases, data not stratified by case	11 cases, data not stratified by case	11 cases, data not stratified by case	11 cases, data not stratified by case	11 cases, data not stratified by case	11 cases, data not stratified by case	11 cases, data not stratified by case
Din <i>et al.</i> , 2016 (2 cases) (38)	A: 9, – B: 9.5, –	11 cases, data not stratified by case	11 cases, data not stratified by case	11 cases, data not stratified by case	11 cases, data not stratified by case	11 cases, data not stratified by case	11 cases, data not stratified by case	11 cases, data not stratified by case
Mahmood <i>et al.</i> , 2017 (39)	15, male	Left parotid gland, 1.7	–	–	Left parotid tumour excision	–	–	–
Rebours <i>et al.</i> , 2017 (40)	<18, –	Parotid gland, –	43 cases, data not stratified by case	43 cases, data not stratified by case	43 cases, data not stratified by case	43 cases, data not stratified by case	43 cases, data not stratified by case	43 cases, data not stratified by case
Ngouajio <i>et al.</i> , 2017 (18)	14, male	Left parotid gland, –	Nil LVI, nil PNI	N0 (0/17 nodes dissected, no evidence of malignancy)	Left superficial parotidectomy	Selective (left level II) neck dissection	Nil	Disease-free at 14 months postoperatively
Majewska <i>et al.</i> , 2015 (41)	17, male	Parotid gland, 4	T2, negative margins	Nil	Partial conservative parotidectomy	Nil	Nil	No evidence of disease at 120 months

**Table S1** (continued)

**Table S1** (continued)

Author, year	Age (years), sex	Site, size (cm)	Tumour invasion	Nodal spread or distant metastasis	Local surgery	Neck dissection	Adjuvant therapy	Outcome
Xu <i>et al.</i> , 2017 (4 cases) (21)	A: 8, male	A: parotid gland, –	A: T1, negative margins, PNI present	Nil	57 cases, data not stratified by case	57 cases, data not stratified by case	57 cases, data not stratified by case	A: no evidence disease at 21 months
	B: 9, male	B: parotid gland, –	B: T1, negative margins, nil PNI					B: no evidence of disease at 111 months
	C: 15, female	C: parotid gland, –	C: T2, positive margins, nil PNI					C: no evidence of disease at 155 months
	D: 18, female	D: lip, –	D: T4a, positive margins, PNI present					D: locoregional recurrence present after 74 months
Shukla <i>et al.</i> , 2018 (42)	17, male	Left parotid gland, 3	Nil LVI, nil PNI	Nil	Left total parotidectomy	Nil	Nil	Disease-free 7 months after surgery
Chen <i>et al.</i> , 2018 (43)	12, female	Parotid gland, –	–	–	–	–	–	–
Shigeta <i>et al.</i> , 2018 (27)	7, male	Left parotid gland, –	T2, negative margins	Nil	Left superficial parotidectomy	Nil	Nil	No long-term complications at 20 months after surgery
Kashiwagi <i>et al.</i> , 2018 (44)	14, female	Parotid gland, 2.5	–	–	–	–	–	–
Forner <i>et al.</i> , 2018 (12)	6, –	Right parotid gland, –	13 cases, data not stratified by case	N2bM0	Right superficial parotidectomy	Selective (level IIa) neck dissection, and left superficial parotidectomy	Radiotherapy (60 Gy)	13 cases, outcome data not stratified by case
Kuwabara <i>et al.</i> , 2018 (2 cases) (45)	A: 14, female	A: parotid gland, –	A: T2	A: nil	A: partial parotidectomy	Nil	Nil	–
	B: 15, female	B: parotid gland, –	B: T2	B: nil	B: parotid tumour excision			
Alhazmi <i>et al.</i> , 2019 (6)	9, female	Left parotid gland, 2.7	–	–	Left lateral lobe parotidectomy with facial nerve dissection	Nil	Nil	–
Anderson <i>et al.</i> , 2019 (46)	12, –	55 cases, data not stratified by case	55 cases, data not stratified by case	55 cases, data not stratified by case	55 cases, data not stratified by case	55 cases, data not stratified by case	55 cases, data not stratified by case	55 cases, data not stratified by case
Hernandez-Prera <i>et al.</i> , 2019 (47)	17, –	–	–	–	–	–	–	–
Black <i>et al.</i> , 2020 (48)	18, male	Right parotid gland, 2.5	T1, involved margins, nil PNI	Nil	Parotid tumour excision	No	No	Asymptomatic 9 months after surgery
Helmy <i>et al.</i> , 2020 (7)	11, female	Right parotid gland, 2.5	Low-grade epithelial tumour	Nil	Right subtotal parotidectomy	No	No	Facial weakness resolved 6 months after surgery, no evidence of recurrence
Yoshino <i>et al.</i> , 2020 (24)	10, female	Right submandibular gland, –	–	–	Submandibular tumour excision	Nil	Radiotherapy	Remission maintained for 6 years
Salgado <i>et al.</i> , 2021 (4 cases) (8)	A: 7, male	A: parotid gland, 1.5	Clear margins, nil LVI, nil PNI	Nil	A, B, D: parotid tumour excision C: submandibular tumour excision	Nil	Nil	A: no recurrence at 4 years 4 months
	B: 9, male	B: parotid gland, 1.3						B: no recurrence at 2 years 6 months
	C: 14, female	C: submandibular gland, 2.1						C: no recurrence at 1 year 6 months
	D: 14, female	D: parotid gland, 1.2						D: no recurrence at 1 year
Kelly <i>et al.</i> , 2022 (2 cases) (22)	A: <18, –	–	–	A: involved lymph nodes	Tumour excision	Yes	–	In remission 24 months post-surgery
	B: <18, –			B: nil				

**Table S1** (continued)

**Table S1** (continued)

Author, year	Age (years), sex	Site, size (cm)	Tumour invasion	Nodal spread or distant metastasis	Local surgery	Neck dissection	Adjuvant therapy	Outcome
Simon <i>et al.</i> , 2022 (4 cases) (49)	A: 9, male	A: right parotid gland, 1.4	A: T1	Nil	A: superficial parotidectomy	Nil	Nil	A, B, C: 2.5 years disease-free D: –
	B: 10, male	B: left hard palate minor salivary gland, 1	B: T1, positive margins on initial excision, negative margins on re-resection		B: tumour excision, then complete re-resection			
	C: 15, male	C: right upper lip minor salivary gland, 0.9	C: T1		C: complete tumour excision			
	D: 18, male	D: right parotid gland, 2.7	D: T2		D: parotid tumour excision			
Cardoni <i>et al.</i> , 2023 (19)	12, female	Right maxillary sinus minor salivary gland, 6.2	High-grade/Ki67 index 60%, nil LVI, PNI present	Nodal spread not documented, though proceeded with radiotherapy to lateral neck nodes	Complete tumour excision	Nil	Neoadjuvant 5-FU, cisplatin, and larotrectinib, adjuvant proton therapy to surgical bed (61.4 Gy) and ipsilateral cervical lymph nodes (54.05 Gy)	Complete remission 16 months after diagnosis
Meng <i>et al.</i> , 2023 (17)	4, male	Right parotid gland, 2.5	Nil LVI, nil PNI	Nil	Parotid tumour excision, then additional resection	Nil	Nil	No recurrence after 2 years of follow-up
Xu <i>et al.</i> , 2022 (26)	7, –	90 cases, data not stratified by case	90 cases, data not stratified by case	90 cases, data not stratified by case	90 cases, data not stratified by case	90 cases, data not stratified by case	90 cases, data not stratified by case	90 cases, data not stratified by case
Current case	16, female	Left parotid gland, 2.9	Margins positive over 1mm front, extensive LVI, focal PNI	1 intraparotid lymph node directly involved by tumour, 4.5 mm deposit of metastatic carcinoma in dissected level IIa lymph node	Left superficial parotidectomy	Excision of left level IIa lymph node, completion left levels II–V neck dissection	Adjuvant radiotherapy to parotid bed and ipsilateral cervical lymph nodes	Disease-free at 12 months postoperatively

SCSG, secretory carcinoma of the salivary glands; T, tumour stage; LVI, lymphovascular invasion; PNI, perineural invasion; N, nodal stage; M, metastasis stage.

## References

29. Griffith C, Seethala R, Chiosea SI. Mammary analogue secretory carcinoma: a new twist to the diagnostic dilemma of zymogen granule poor acinic cell carcinoma. *Virchows Arch* 2011;459:117-8.
30. Connor A, Perez-Ordoñez B, Shago M, et al. Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. *Am J Surg Pathol* 2012;36:27-34.
31. Woo J, Seethala RR, Sirintrapun SJ. Mammary analogue secretory carcinoma of the parotid gland as a secondary malignancy in a childhood survivor of atypical teratoid rhabdoid tumor. *Head Neck Pathol* 2014;8:194-7.
32. Keisling M, Bianchi M, Pascasio JM. Mammary analog secretory carcinoma of salivary gland in a 5 year old: case report. *Int J Pediatr Otorhinolaryngol Extra* 2014;9:163-5.
33. Quattlebaum SC, Roby B, Dishop MK, et al. A pediatric case of mammary analogue secretory carcinoma within the parotid. *Am J Otolaryngol* 2015;36:741-3.
34. Shah AA, Wenig BM, LeGallo RD, et al. Morphology in conjunction with immunohistochemistry is sufficient for the diagnosis of mammary analogue secretory carcinoma. *Head Neck Pathol* 2015;9:85-95.
35. Urano M, Nagao T, Miyabe S, et al. Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers. *Hum Pathol* 2015;46:94-103.
36. Ito Y, Ishibashi K, Masaki A, et al. Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic and molecular study including 2 cases harboring ETV6-X fusion. *Am J Surg Pathol* 2015;39:602-10.
37. Khurram SA, Sultan-Khan J, Atkey N, et al. Cytogenetic and immunohistochemical characterization of mammary analogue secretory carcinoma of salivary glands. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2016;122:731-42.
38. Din NU, Fatima S, Kayani N. Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic study of 11 cases. *Ann Diagn Pathol* 2016;22:49-53.
39. Mahmood H, Fatima H, Faheem M. Mammary Analogue Secretory Carcinoma of Parotid Gland in a Teenage Boy. *J Coll Physicians Surg Pak* 2017;27:579-81.
40. Rebours C, Couloigner V, Galmiche L, et al. Pediatric salivary gland carcinomas: Diagnostic and therapeutic management. *Laryngoscope* 2017;127:140-7.
41. Majewska H, Skálová A, Stodulski D, et al. Mammary analogue secretory carcinoma of salivary glands: a new entity associated with ETV6 gene rearrangement. *Virchows Arch* 2015;466:245-54.
42. Shukla S, Kashyap A, Sharma S, et al. Mammary Analogue secretory carcinoma—a salivary gland neoplasm: case report of an exceptionally rare tumour. *J Clin Diagn Res* 2018;12:ED01-2.
43. Chen YC, Hsu HT, Lin YH, et al. Mammary analog secretory carcinoma of the parotid gland: A case of a 12-year-old Taiwanese girl. *Int J Pediatr Otorhinolaryngol Case Rep* 2018;20:14-7.
44. Kashiwagi N, Nakatsuka SI, Murakami T, et al. MR imaging features of mammary analogue secretory carcinoma and acinic cell carcinoma of the salivary gland: a preliminary report. *Dentomaxillofac Radiol* 2018;47:20170218.
45. Kuwabara H, Yamamoto K, Terada T, et al. Hemorrhage of MRI and Immunohistochemical Panels Distinguish Secretory Carcinoma From Acinic Cell Carcinoma. *Laryngoscope Investig Otolaryngol* 2018;3:268-74.
46. Anderson JL, Haidar YM, Armstrong WB, et al. Analysis of Clinical Features of Mammary Analog Secretory Carcinoma Using the Surveillance, Epidemiology, and End Results Database. *JAMA Otolaryngol Head Neck Surg* 2019;145:91-3.
47. Hernandez-Prera JC, Holmes BJ, Valentino A, et al. Macrocytic (Mammary Analogue) Secretory Carcinoma: An Unusual Variant and a Pitfall in the Differential Diagnosis of Cystic Lesions in the Head and Neck. *Am J Surg Pathol* 2019;43:1483-92.
48. Black M, Liu CZ, Onozato M, et al. Concurrent Identification of Novel EGFR-SEPT14 Fusion and ETV6-RET Fusion in Secretory Carcinoma of the Salivary Gland. *Head Neck Pathol* 2020;14:817-21.
49. Simon CT, McHugh JB, Rabah R, et al. Secretory Carcinoma in Children and Young Adults: A Case Series. *Pediatr Dev Pathol* 2022;25:155-61.